Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology)

Trial Profile

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer and Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Excluding Predominant Squamous Cell Histology)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ARIES
  • Sponsors Genentech
  • Most Recent Events

    • 08 Jan 2016 Results of patients with non-small-cell lung cancer (n=1967) published in the Pharmacoepidemiology and Drug Safety
    • 02 Jun 2015 Results assessing post-progression survival of PointBreak, ARIES and ECOG 4599 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 24 Jan 2013 Results from an analysis by gender will be presented at the 2013 ASCO Gastrointestinal Cancers Symposium according to a Sarah Cannon Research Institute media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top